What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?

被引:79
|
作者
Petrini, P [1 ]
机构
[1] Karolinska Hosp, Dept Paediat, S-17176 Stockholm, Sweden
关键词
haemophilia; prophylaxis; trough level;
D O I
10.1046/j.1365-2516.2001.00471.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In order to prevent arthropathy, prophylaxis has to start at a young age before recurrent joint bleedings have taken place. The use of central venous lines has facilitated an early beginning to treatment, but due to side-effects, most European paediatricians prefer peripheral injections whenever possible. By starting primary prophylaxis at the age of 1-2 years with one injection weekly, the need for surgical implants may be reduced. In this study, only four of 34 boys born 1988-98 with severe haemophilia A or B needed a Port-a-Cath(R) for primary prophylaxis. Trough levels were measured in these patients and 79% showed a trough level < 1%, while 21% reached a level > 1%. Despite this, joint bleedings during 1998 were rare in both groups [0-4] and 59% of the boys with trough levels < 1% did not report any haemartroses during that year. Mean annual joint bleedings were the same in both groups [0.70, 0.71]. The lowest effective level of factors VIII and IX must be determined individually for each patient on primary or secondary prophylaxis.
引用
收藏
页码:99 / 102
页数:4
相关论文
共 50 条
  • [41] On-demand but not prophylactic treatment with FVIII concentrate increase thrombin activatable fibrinolysis inhibitor activation in severe haemophilia A patients
    Mikovic, D.
    Woodhams, B. J.
    Holmstrom, M.
    Elezovic, I.
    Antovic, A.
    Mobarrez, F.
    Elfvinge, P.
    Antovic, J. P.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2012, 34 (01) : 35 - 40
  • [42] Perception of the quality of life of families and patients with severe Haemophilia A in prophylactic treatment with Emicizumab or FVIII lyophilisate: Focus group study
    Gonzalez Ruiz, Lina
    Zuniga Contreras, Pamela
    Rosas, Amaia
    Nielsen Guzman, Benjamin
    HAEMOPHILIA, 2023, 29 : 25 - 26
  • [43] STUDIES ON DOSAGE IN PROPHYLACTIC COUMARINE TREATMENT OF PATIENTS WITH CORONARY OCCLUSION
    FROLAND, A
    ACTA MEDICA SCANDINAVICA, 1961, 169 (05): : 545 - +
  • [44] Is on-demand treatment effective in patients with severe haemophilia?
    Aznar, J. A.
    Marco, A.
    Jimenez-Yuste, V.
    Fernandez-Fontecha, E.
    Perez, R.
    Soto, I.
    Parra, R.
    Moreno, M.
    Mingot, M. E.
    Moret, A.
    HAEMOPHILIA, 2012, 18 (05) : 738 - 742
  • [45] Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy
    Giampaolo, A.
    Abbonizio, F.
    Puopolo, M.
    Arcieri, R.
    Mannucci, P. M.
    Hassan, H. J.
    TRANSFUSION MEDICINE, 2011, 21 (04) : 280 - 284
  • [46] Prevalence of FVIII inhibitors in severe haemophilia A patients: Effect of treatment and genetic factors in an Indian population
    David, Sachin
    Nair, Sukesh C.
    Singh, G. Surender
    Abu Alex, Ansu
    Ganesan, Saravanan
    Palani, Hamenth Kumar
    Balasundaram, Nithya
    Lakshmi, Kavitha M.
    Joshi, Aditi
    Kannan, S.
    Korula, Anu
    Aboobacker, Fouzia Nambiatheyil
    Abraham, Aby
    George, Biju
    Apte, Shashikant Janardan
    Srivastava, Alok
    Mathews, Vikram
    HAEMOPHILIA, 2019, 25 (01) : 67 - 74
  • [47] Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres
    Morfini, M.
    Auerswald, G.
    Kobelt, R. A.
    Rivolta, G. F.
    Rodriguez-Martorell, J.
    Scaraggi, F. A.
    Altisent, C.
    Blatny, J.
    Borel-Derlon, A.
    Rossi, V.
    HAEMOPHILIA, 2007, 13 (05) : 502 - 507
  • [48] Experience of treatment in children with severe haemophilia B in A single centre
    Gil Barroso, C.
    Perez Garcia, P.
    Diaz Roldan, B.
    Dominguez Rodriguez, J. F.
    HAEMOPHILIA, 2024, 30 : 113 - 114
  • [49] Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A
    Xue, Feng
    Zhao, Xielan
    Sun, Jing
    Zeng, Xiaojing
    Yang, Fenge
    Xu, Ming
    Yu, Ziqiang
    Gu, Weiying
    Feng, Ying
    Li, Wenqian
    Zheng, Changcheng
    Bi, Hui
    Xie, Liangzhi
    Gai, Wenlin
    Yang, Renchi
    HAEMOPHILIA, 2021, 27 (05) : 814 - 822
  • [50] Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres
    Virginie Nerich
    Edgar Tissot
    Albert Faradji
    Karine Demesmay
    Marie Anne Bertrand
    Jean-Louis Lorenzini
    Marie-Elisabeth Briquel
    Patricia Pouzol
    Marie-Christine Woronoff-Lemsi
    Pharmacy World & Science, 2008, 30 : 287 - 292